Subscribe To

Price Alert Latest News Economic Calendar News

PAVM / PAVmed Highlights First-In-Human Implantations of its PortIO Infusion System

PAVmed Inc (NASDAQ: PAVM) announced the successful implantation of its PortIO Intraosseous Infusion System in three patients as part of a first-in-human (FIH) clinical study of up to 40 patients. No complications have occurred. Read More

Demo Live Account See Partner Details

Content Topics

Pavmed

Highlights

First

In

Human

Implantations

Portio

First in human

Infusion

System

Stock

PAVM

Posted: Mar 17 2022, 11:51

Author Name: Benzinga

PAVM News

By Zacks Investment Research
August 30, 2023

Here's Why PAVmed Inc. (PAVM) Is a Great 'Buy the Bottom' Stock Now

PAVmed Inc. (PAVM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this

By Seeking Alpha
August 16, 2023

PAVmed Inc. (PAVM) Q2 2023 Earnings Call Transcript

PAVmed Inc. (NASDAQ:PAVM ) Q2 2023 Earnings Conference Call August 16, 2023 8:30 AM ET Company Participants Michael Parks - Vice President of Investor

By InvestorPlace
May 24, 2023

3 Biotech Stocks That Could Turn $1,000 into $10,000 by 2024

Developing groundbreaking drugs and devices entails high costs, uncertain regulatory approval, and lucrative revenues. Those factors and more culminat

By Zacks Investment Research
March 17, 2023

PAVmed Inc. (PAVM) Upgraded to Strong Buy: Here's What You Should Know

PAVmed Inc. (PAVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Bu

By Seeking Alpha
March 15, 2023

PAVmed Inc. (PAVM) Q4 2022 Earnings Call Transcript

PAVmed Inc. (NASDAQ:PAVM ) Q4 2022 Earnings Conference Call March 15, 2023 8:30 AM ET Company Participants Michael Parks – Vice President, Investor

By Seeking Alpha
November 15, 2022

PAVmed Inc. (PAVM) Q3 2022 Earnings Call Transcript

PAVmed Inc. (NASDAQ:PAVM ) Q3 2022 Earnings Conference Call November 15, 2022 4:30 PM ET Company Participants Adrian Miller - VP, IR Lishan Aklog - Ch

By Business Wire
November 3, 2022

PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2022

NEW YORK--(BUSINESS WIRE)---- $PAVM #1x1meetings--PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical device company today annou

By Seeking Alpha
May 12, 2022

PAVmed Inc.'s (PAVM) CEO Lishan Aklog on Q1 2022 Results - Earnings Call Transcript

PAVmed Inc. (NASDAQ:PAVM ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Adrian Miller - VP, IR Lishan Aklog - Chairma

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.